TWEAK Protein (AA 97-249)

Catalog No. ABIN2666449

This Recombinant TWEAK protein is produced in Escherichia coli (E. coli).

Quick Overview for TWEAK Protein (AA 97-249) (ABIN2666449)

Target: TWEAK (TNFSF12) (Tumor Necrosis Factor (Ligand) Superfamily, Member 12 (TNFSF12))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Biochemical Assay (BCA)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 97-249

Endotoxin Level:

Less than 0.1 ng per μg of protein.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 < 10 ng/ml, corresponding to a specific activity of > 1 x 107 units/mg, as determined by the dose dependent stimulation of production of IL-8 by human PBMC.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: For maximum results, quick spin vial prior to opening. Reconstitute in 10 mM sodium phosphate, pH 7.5 to a concentration of 1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer containing a carrier protein such as 0.1 % BSA and store working aliquots at -20 °C to -80 °C.

Buffer: Lyophilized

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored at -20°C or -70°C.

Target Details

Target: TWEAK (TNFSF12) (Tumor Necrosis Factor (Ligand) Superfamily, Member 12 (TNFSF12))

Alternative Name: TWEAK

Background: TWEAK (TNFSF12) is a "TNF-like weak inducer" of apoptosis through a non-death domain-dependent mechanism. TWEAK is a type II membrane protein which exhibits a single internal hydrophobic domain of 27 amino acids in the N-terminal region. TWEAK is proteolytically cleaved to produce a soluble cytokine that signals as a trimerized molecule. Fibroblast growth factor-inducible 14 (Fn14)/TWEAKR has been described as a receptor for TWEAK, and it is associated with proliferation of endothelial cells and angiogenesis. However, TWEAK mediates signal transduction and linear differentiation of monocyte/macrophage cells lacking Fn14/TWEAKR, suggesting that such cells contain an alternative TWEAK receptor. Elevated levels of TWEAK and/or Fn14 have been found to be associated with the pathogenesis of rheumatoid arthritis, skeletal muscle wasting, systemic lupus erythematosus, multiple sclerosis, stroke, neuroinflammation and neurodegeneration, and several types of cancer. The pathological functions of TWEAK are primarily attributed to its ability to induce the expression of several proinflammatory cytokines, chemokines, cell adhesion molecules, and matrix-degrading enzymes mainly through the activation of NF-κB, a major proinflammatory transcription factor. It has been described that CD163 (a scavenger receptor) might be acting as a receptor decoy for the ligand TWEAK.

Molecular Weight: The 154 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 17 kDa.

Pathways: Apoptosis